DIA 2020
June 14-18, 2020
Virtual EST
Menu Back to Committee

Program Committee

  • Jonathan Raymond Andrus, MS
    Jonathan Raymond Andrus, MS • Chief Strategy Officer
    Clinical Ink, United States
  • Matt Baldwin, MS
    Matt Baldwin, MS • Senior Biostatistician
    Advance Research Associates, Inc (ARA), United States
  • Amy Bertha
    Amy Bertha • Executive Director, Regulatory Policy
    Bayer, United States
  • Poonam Bordoloi, PharmD
    Poonam Bordoloi, PharmD • Executive Director, Head of Global Medical Affairs Capabilities
    Organon & Co., United States
  • David Bowers, PharmD
    David Bowers, PharmD • Senior Director, Operations
    PPD, United States
  • Philip (P.J.) Brooks, PhD
    Philip (P.J.) Brooks, PhD • Deputy Director, Office of Rare Diseases Research
    National Center for Advancing Translational Sciences (NCATS), NIH, United States
  • Jennifer Burgess, MBA, MPH
    Jennifer Burgess, MBA, MPH • Vice President, Global Engagement and Communications
    TransCelerate BioPharma Inc., United States
  • Bill Byrom, PhD
    Bill Byrom, PhD • Principal, eCOA Science
    Signant Health , United Kingdom
  • Susan Callery-D'Amico, BSN
    Susan Callery-D'Amico, BSN • Vice President, R&D Quality Assurance
    AbbVie, Inc., United States
  • Meghana Chalasani, MHA
    Meghana Chalasani, MHA • Lead, Science Strategies, Office of New Drugs, CDER
    FDA, United States
  • Yeh-Fong Chen, PhD
    Yeh-Fong Chen, PhD • Mathematical Statistician (Team Lead), Office of Translational Sciences, CDER
    FDA, United States
  • Karla Childers, MS
    Karla Childers, MS • Bioethics & Strategic Projects Leader, Office of the Chief Medical Officer
    Johnson & Johnson, United States
  • Deborah Collyar
    Deborah Collyar • President
    Patient Advocates In Research (PAIR), United States
  • Freda Cooner, PhD
    Freda Cooner, PhD • Director, Global Biostatistics
    Amgen, United States
  • Stephanie Y. Crawford, PhD, MPH, MS
    Stephanie Y. Crawford, PhD, MPH, MS • Professor, Pharmacy Systems, Outcomes and Policy
    University of Illinois at Chicago, United States
  • Sonya Eremenco, MA
    Sonya Eremenco, MA • Executive Director, PRO Consortium
    Critical Path Institute, United States
  • Ron Fitzmartin, PhD, MBA
    Ron Fitzmartin, PhD, MBA • Senior Informatics Advisor, Office of the Director, CBER
    FDA, United States
  • David Fryrear, MS
    David Fryrear, MS • Executive Vice President and Head of Quality Assurance, Medical and Development
    Astellas, United States
  • M. Scott Furness, PhD
    M. Scott Furness, PhD • Deputy Director, Office of New Drug Products, OPQ, CDER
    FDA, United States
  • William Gregory, PhD
    William Gregory, PhD • Senior Director, Safety and Risk Management
    Pfizer Inc, United States
  • Marianne Hamilton Lopez, PhD, MPA
    Marianne Hamilton Lopez, PhD, MPA • Research Director, Value-Based Payment Reform
    Duke-Margolis Center For Health Policy, United States
  • Sabine Haubenreisser, PhD, MSc
    Sabine Haubenreisser, PhD, MSc • Principal Scientific Administrator, Stakeholders and Communication Division
    European Medicines Agency, Netherlands
  • Jeremy Jokinen, PhD, MS
    Jeremy Jokinen, PhD, MS • Vice President and Head, Global Risk Management and Epidemiology
    Bristol Myers Squibb, United States
  • Nadina Jose, MD
    Nadina Jose, MD • Assistant Professor, School of Health Professions, MS Clinical Research Program
    Rutgers, The State University of New Jersey, United States
  • Sean D. Kennedy, MPH
    Sean D. Kennedy, MPH • Global Head, Real World Evidence
    ICON plc, United States
  • Agnes Victoria Klein, MD
    Agnes Victoria Klein, MD • Senior Medical Advisor
    Health Canada, Canada
  • Darryl L'Heureux, PhD, MPharm, MSc
    Darryl L'Heureux, PhD, MPharm, MSc • Director, Clinical Science, Medical Writing, and Publications
    Ambrx, Inc, United States
  • Erik Laughner
    Erik Laughner • Project Manager, Business Operations Staff, OD, CBER
    FDA, United States
  • Rebecca Lipsitz, PhD
    Rebecca Lipsitz, PhD • Senior Director, TA Regulatory Intelligence and Portfolio Policy, Late R&I RA
    AstraZeneca, United States
  • Christopher Marrone, PharmD, RPh
    Christopher Marrone, PharmD, RPh • Outcomes Liaison
    Eli Lilly and Company, United States
  • Chris Matheus, MBA
    Chris Matheus, MBA • Chief Commercial & Networking Officer
    Global Life Sciences Alliance, United States
  • K. Kimberly McCleary
    K. Kimberly McCleary • Founder and Chief Executive Officer
    The Kith Collective, LLC, United States
  • Ann Meeker-O'Connell, MS
    Ann Meeker-O'Connell, MS • Director, Office of Clinical Policy, OCPP, OC
    FDA, United States
  • Christine Moore, PhD
    Christine Moore, PhD • Executive Director, External Advocacy and Quality
    Organon & Co., United States
  • Jean M. Mulinde, MD
    Jean M. Mulinde, MD • Medical Officer, Policy Advisor, Division of Clinical Compliance Evaluation, OSI
    FDA, United States
  • Nobumasa Nakashima, PhD
    Nobumasa Nakashima, PhD • Associate Executive Director for International Programs
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Michael Neidl, MBA, MS, MSc
    Michael Neidl, MBA, MS, MSc • Senior Clinical Research Executive
    Clinical Research Consultant, LLC, United States
  • Anita Nelsen
    Anita Nelsen • Executive Vice President, Translational Medicine
    Parexel, United States
  • David O Olaleye, PhD, MSc
    David O Olaleye, PhD, MSc • Senior Manager and Principal Research Statistician
    SAS Institute Inc., United States
  • David J Pepperl, PhD
    David J Pepperl, PhD • Senior Consultant and Nonclinical Group Leader
    Biologics Consulting, United States
  • Sissi Pham, PharmD
    Sissi Pham, PharmD • Chief Executive Officer
    AESARA, United States
  • Paul Phillips
    Paul Phillips • Director (Acting), Office of Program Operations, OND, CDER
    FDA, United States
  • James E. Polli, PhD
    James E. Polli, PhD • Prof, Ralph F Shangraw/Noxell Endowed Chair in Industrial Pharmacy/Pharmaceutic
    University of Maryland School of Pharmacy, United States
  • Margaret Richards, PhD, MPH
    Margaret Richards, PhD, MPH • Senior Research Leader, Real World Evidence
    Evidera, United States
  • Steven L. Roberds, PhD
    Steven L. Roberds, PhD • Chief Scientific Officer
    Tuberous Sclerosis Alliance, United States
  • Khyati Roberts, RPh
    Khyati Roberts, RPh • Head US/Canada, Regulatory Policy and Intelligence
    Abbvie, United States
  • Khushboo Sharma, MBA
    Khushboo Sharma, MBA • Vice President, Science and Regulatory Affairs
    BIO, United States
  • Nancy Slater, MBA, PMP
    Nancy Slater, MBA, PMP • Senior Director, Portfolio Program Management Therapeutic Area Head
    AbbVie, Inc., United States
  • Nancy Pire Smerkanich, DrSc, MS
    Nancy Pire Smerkanich, DrSc, MS • Assistant Professor Regulatory & Quality Sciences
    University of Southern California School of Pharmacy, United States
  • Meredith Smith, PhD, MPA, FISPE
    Meredith Smith, PhD, MPA, FISPE • Director, Risk Management, Global Drug Safety, Research and Development
    Alexion Pharmaceuticals, United States
  • Elizabeth Somers, MS
    Elizabeth Somers, MS • Executive Director of Infectious Disease, Global Project and Alliance Management
    Merck & Co., Inc., United States
  • Evelyn Soo, PhD
    Evelyn Soo, PhD • Director, Bureau of Gastroenterology, Infection and Viral Diseases, HPFD
    Health Canada, Canada
  • Jeffrey N. Stuart, PhD
    Jeffrey N. Stuart, PhD • Associate Vice President, Global Regulatory Affairs
    Merck & Co., Inc., United States
  • Ling Su, PhD
    Ling Su, PhD • Professor
    Shenyang Pharmaceutical University, China
  • Rachel Turow, JD, MPH
    Rachel Turow, JD, MPH • Associate General Counsel, Regulatory Law & Policy; Head, U.S. Regulatory Policy
    Teva Pharmaceutical Industries Ltd., United States
  • Kristin Voorhees, MA
    Kristin Voorhees, MA • Director, Patient Advocacy
    Ultragenyx Pharmaceutical, United States
  • Nancy Watanabe, MS, PMP
    Nancy Watanabe, MS, PMP • Executive Director, New Market Development Project Leadership
    BeiGene, Inc., United States
  • Judith Zander, MD
    Judith Zander, MD • Director, Office of Pharmacovigilance and Epidemiology, OSE, CDER
    FDA , United States
Load More